Login to Your Account



Amgen Girds For Competition In High-Stakes RA Therapy Field

By Randall Osborne


Monday, October 28, 2002
A longstanding squabble between Amgen Inc. and Johnson & Johnson over epoetin alfa ended last week with an arbitrator's $150 million decision favoring the former, just as another skirmish - not legal - began to heat up between the pair. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription